BiomX Inc.

BiomX Inc. (NYSE American: PHGE) is a clinical-stage biotechnology company focused on developing phage-based therapies for chronic bacterial diseases, including inflammatory bowel disease, acne, and primary sclerosing cholangitis. The company entered public markets in October 2019 through a business combination with Chardan Healthcare Acquisitions Corp, a blank-check vehicle sponsored by Chardan Capital Markets that completed its IPO earlier that year. BiomX, originally founded in Israel, is listed on NYSE American and continues to advance its bacteriophage therapeutic pipeline across multiple clinical programs. Investors seeking full filing data, sponsor details, and deal history for PHGE can sign up for complete coverage at SpacDesk.